Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States
Open Access
- 28 April 2016
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 91 (8) , 770-775
Abstract
We aimed to comprehensively study sex differences in disease and patients' characteristics, treatment and outcomes in patients with follicular lymphoma (FL) in the United States (USA) utilizing the National LymphoCare Study registry (2004–2014). Among evaluable males (n = 1277) and females (n = 1375) with FL, females less commonly received anthracyclines and were more likely to receive rituximab monotherapy. Overall response rates were comparable between sex groups. With a median follow‐up of 8.1 years, male sex emerged as an adverse factor for PFS (HR, 0.84, 95% CI, 0.72–0.97). Lymphoma‐related mortality (HR, 0.46; 0.23–0.93) and overall survival (HR, 0.63; 0.41–0.97) favored females aged ≤60 years. There are subtle differences in outcomes between male and female FL patients diagnosed and treated in the contemporary era. These data represent the largest prospective analysis of FL patients in the USA based on sex and can aid design of clinical trials for this disease. Am. J. Hematol. 91:770–775, 2016.Keywords
Funding Information
- Genentech Inc., South San Francisco, CA/F
- Hoffmann-La Roche Ltd, Basel, Switzerland
This publication has 20 references indexed in Scilit:
- Suboptimal dosing of rituximab in male and female patients with DLBCLBlood, 2014
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialThe Lancet, 2013
- The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCLBlood, 2012
- Racial differences in presentation and management of follicular non‐Hodgkin lymphoma in the United StatesCancer, 2012
- Primary gastrointestinal follicular lymphoma involving the duodenal second portion is a distinct entity: A multicenter, retrospective analysis in JapanCancer Science, 2011
- Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy*European Journal of Haematology, 2010
- Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor ProjectJournal of Clinical Oncology, 2009
- Follicular Lymphoma in the United States: First Report of the National LymphoCare StudyJournal of Clinical Oncology, 2009
- Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemiaBlood, 2004
- Follicular Lymphoma International Prognostic IndexBlood, 2004